This trial is no longer recruiting

Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.

Not recruiting
Phase 3

MK-8527

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT07044297

Conditions

Human Immunodeficiency Virus (HIV)

HIV Pre-Exposure Prophylaxis

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Accepted

Interventions

MK-8527

FTC/TDF

Placebo to MK-8527

Placebo to FTC/TDF

Study Details

Brief summary:

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.

The goals of this study are to learn:

  • If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day
  • About the safety of MK-8527 and if people tolerate it

Conditions

Human Immunodeficiency Virus (HIV)

HIV Pre-Exposure Prophylaxis

Study ID

NCT07044297

Start date

Jul 31, 2025

Status verified date

Sep, 2026

Completion date

Jul 22, 2027

Anticipated

Primary completion date

Jul 22, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Accepted

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results
  • Is a cisgender man, transgender woman (assigned male sex at birth), transgender man (assigned female sex at birth), or gender nonbinary person
  • Has had condomless receptive anal sex in the 12 months prior to screening (not including sex occurring in a mutually monogamous relationship) and has at least 1 of the following: receptive anal sex with 2 or more partners in the 3 months prior to screening (regardless of condom use), rectal or urethral gonorrhea or chlamydia or incident syphilis in the 6 months prior to screening, or any self-reported stimulant drug use with sex in the 3 months prior to screening
  • Weighs ≥35 kg

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has hypersensitivity or other contraindication to any component of the study interventions
  • Has evidence of acute or chronic hepatitis B infection
  • Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ anal or cervical cancers
  • Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time
  • Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration
  • Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1
  • Is expecting to donate eggs at any time during the study

Study Design

Enrollment

4390 participants

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: MK-8527

Participants will receive 11 mg MK-8527 once monthly (QM) and placebo to FTC/TDF once daily (QD) for up to approximately 2 years. Participants will then receive open-label 200 mg FTC/245 mg TDF QD for an additional 28 days.

active comparator: FTC/TDF

Participants will receive 200 mg FTC/245 mg TDF QD and placebo to MK-8527 QM for up to approximately 2 years. Participants will then receive open-label 200 mg FTC/245 mg TDF QD for an additional 28 days.

Interventions

MK-8527

Oral tablet

FTC/TDF

Oral tablet

Placebo to MK-8527

Placebo tablet matched to MK-8527

Placebo to FTC/TDF

Placebo tablet matched to FTC/TDF

Primary outcome measure

  • Number of Participants With Adjudicated Human Immunodeficiency Virus Type 1 (HIV-1) Infection [ Time Frame: Up to approximately 2 years ]
  • Number of Participants Who Experience At Least One Adverse Event (AE) [ Time Frame: Up to approximately 2 years ]
  • Number of Participants Who Discontinue Study Intervention Due to an AE [ Time Frame: Up to approximately 2 years ]

Central Contacts and Locations

More Information

Sponsor

Merck Sharp & Dohme LLC

Last update posted

Sep 18, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-12. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-09-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.